Wondering how retatrutide and survodutide compare for weight loss? Both are experimental once-weekly shots, and each maker has announced Phase 3 results. Eli Lilly says retatrutide works on three hormone receptors (GIP, GLP-1 and glucagon) and announced up to 28.3% average weight loss at its top dose on the efficacy count (company-announced, May 21, 2026) in an 80-week trial. Boehringer Ingelheim says survodutide works on two (GLP-1 and glucagon) and announced up to 16.6% on the efficacy count (company-announced, April 28, 2026) in its 76-week SYNCHRONIZE-1 trial. Those numbers come from separate trials, so they are a starting point for your question, not a ranking.
Neither drug is FDA approved, and neither is available by prescription from any pharmacy, clinic or website as of November 20, 2026. Both are still under study. Here's what we'll walk through: what each drug is, the weight results, the side effects, the liver and heart data, and a few questions to bring to your own clinician.
Quick heads-up: this page has affiliate links, and we may earn a commission if you buy through them.
Retatrutide vs survodutide at a glance
Quick facts as of November 20, 2026:
| Fact | Retatrutide | Survodutide |
|---|---|---|
| Maker | Eli Lilly | Boehringer Ingelheim (licensed from Zealand Pharma) |
| Receptors targeted | Three: GIP, GLP-1 and glucagon | Two: GLP-1 and glucagon |
| Phase 3 dosing | Once-weekly injection; 4, 9 and 12 mg in TRIUMPH-1 and -2 (9 and 12 mg in TRIUMPH-3 and -4), starting at 2 mg and stepped up every four weeks | Once-weekly injection; 3.6 mg or 6.0 mg |
| FDA status | Not approved; investigational | Not approved; investigational |
| Company timing | Lilly plans a U.S. submission in the first quarter of 2027 | Boehringer is moving forward with global submissions in obesity, and its releases give no filing date |
| Length of Phase 3 obesity trials | 80 weeks (TRIUMPH-1, -2, -3); 68 weeks (TRIUMPH-4) | 76 weeks (SYNCHRONIZE-1, -2) |
| Heart outcomes trial | TRIUMPH-3 results reported July 23, 2026; TRIUMPH-Outcomes still running | SYNCHRONIZE-CVOT results (5,530 adults) reported November 9, 2026 |
| Liver-focused trials | SYNERGY-Outcomes master protocol, which includes retatrutide, is recruiting | SYNCHRONIZE-MASLD completed; LIVERAGE and LIVERAGE-Cirrhosis are recruiting |
What are retatrutide and survodutide?
Retatrutide is Eli Lilly's experimental medicine. Lilly describes it as a once-weekly GIP, GLP-1 and glucagon triple receptor agonist, so it acts on three receptors at once (Lilly's July 23, 2026 release).
Survodutide is Boehringer Ingelheim's experimental medicine. Boehringer calls it a glucagon/GLP-1 dual agonist, so it acts on two receptors and doesn't include GIP. Boehringer licensed it from Zealand Pharma and is solely responsible for its global development and commercialization.
The earlier Phase 2 study of retatrutide, published in the New England Journal of Medicine in 2023, enrolled 338 adults with obesity for 48 weeks. At 48 weeks, the 12 mg group averaged a 24.2% drop in body weight, compared with 2.1% on placebo (Phase 2 retatrutide study in NEJM).
The Phase 2 survodutide study, published in The Lancet Diabetes and Endocrinology in 2024, enrolled 387 adults without diabetes for 46 weeks. Its highest dose, 4.8 mg, averaged a 14.9% drop, compared with 2.8% on placebo (Lancet Diabetes and Endocrinology study).
Which is better, retatrutide or survodutide?
Neither drug can be ranked from the trials so far. ClinicalTrials.gov lists no study that tests the two together, and the Phase 3 obesity trials reported so far compared each drug with placebo. A bigger number in one trial doesn't show that drug works better than the other.
Why the trials can't be lined up
- People. TRIUMPH-1 and SYNCHRONIZE-1 both enrolled adults without diabetes, but each company's other Phase 3 trials enrolled different groups, such as adults with type 2 diabetes.
- Doses. Retatrutide was studied at 4, 9 and 12 mg. Survodutide was studied at 3.6 mg and 6.0 mg.
- Length. TRIUMPH-1 ran 80 weeks and SYNCHRONIZE-1 ran 76 weeks.
- Counting. The two companies used different ways of counting results, explained below.
- Placebo. The placebo groups lost different amounts: 2.2% in TRIUMPH-1 and 3.2% in SYNCHRONIZE-1, counting results as if everyone stayed on the drug.
What the two ways of counting mean
The efficacy count shows results as if everyone stayed on the drug. The treatment-regimen count shows the effect of the treatment whether or not people stopped or interrupted it or used other weight-loss treatment. Switching between the two moves the headline number, as it did in both companies' trials.
What did the Phase 3 weight-loss trials report?
Both companies have announced Phase 3 results. ClinicalTrials.gov record NCT05929066 is TRIUMPH-1, and ClinicalTrials.gov record NCT06066515 is SYNCHRONIZE-1. The table's source column labels each row as company-announced or peer-reviewed. For more retatrutide numbers, see our retatrutide trial results page.
| Trial | Phase, population and length | Dose | Weight change, efficacy estimand (placebo) | Source and date |
|---|---|---|---|---|
| Retatrutide TRIUMPH-1 | Phase 3; adults with obesity, no diabetes; 80 weeks; 2,339 adults | 12 mg | -28.3% (placebo -2.2%); treatment-regimen -25.0% (placebo -3.9%) | Company-announced: Lilly release, May 21, 2026 |
| Retatrutide TRIUMPH-2 | Phase 3; adults with type 2 diabetes and obesity; 80 weeks; 1,152 adults | 12 mg | -20.8% (placebo -4.0%); A1C (a blood sugar measure) -1.5% vs -0.2% | Company-announced: Lilly release, July 23, 2026 |
| Survodutide SYNCHRONIZE-1 | Phase 3; adults with obesity, no diabetes; 76 weeks | 3.6 mg or 6.0 mg | Up to -16.6% (placebo -3.2%) | Company-announced: Boehringer topline, April 28, 2026 |
| Survodutide SYNCHRONIZE-2 | Phase 3; adults with obesity and type 2 diabetes; 76 weeks | 3.6 mg or 6.0 mg | Up to -13.1% (placebo -3.1%); treatment-regimen -9.8% at 6.0 mg (placebo -3.9%) | Company-announced: Zealand Pharma, October 1, 2026; peer-reviewed (journal): NEJM, October 2026 |
TRIUMPH-1's results were later published in a NEJM paper on TRIUMPH-1, which reports the same treatment-regimen figure for the 12 mg dose, -25.0% vs -3.9%. In an extension, 532 participants with a baseline BMI of 35 or higher went on to 104 weeks and reached -30.3% on 12 mg at the maximum tolerated dose, on the efficacy count (Lilly's May 21, 2026 release).
Boehringer's April 28, 2026 topline for SYNCHRONIZE-1 (company-announced), as reported by PharmaTimes report on SYNCHRONIZE-1, was an average loss of up to 16.6% vs 3.2% on placebo on the efficacy count over 76 weeks.
Has retatrutide been compared with semaglutide or tirzepatide?
Lilly is running two head-to-head studies, and one has reported. TRANSCEND-T2D-2 compared retatrutide with semaglutide 2 mg in adults with type 2 diabetes on metformin, and Lilly announced the results on October 28, 2026. On the efficacy count, weight fell 20.9% on 12 mg and 19.5% on 9 mg, vs 9.4% on semaglutide. A1C dropped 2.2% on both retatrutide doses vs 1.8% on semaglutide. Stopping because of adverse events was 4.8% and 7.9% on the two retatrutide doses vs 2.7% on semaglutide. Lilly's release says the 12 mg dose beat semaglutide on A1C, a blood sugar measure, and the 9 mg dose was not worse. These are the company's numbers (AJMC's report on TRANSCEND-T2D-2).
TRIUMPH-5, which compares retatrutide with tirzepatide in adults with obesity, is listed on ClinicalTrials.gov as active, not recruiting, with primary completion estimated for November 2026 (NCT06662383).
What are the side effects of retatrutide and survodutide?
The most common side effects in both groups of trials were stomach-related. Retatrutide trials also reported abnormal skin sensation, which Lilly calls dysesthesia; this article has no survodutide figure for it. The table sets Lilly's TRIUMPH-1 numbers for retatrutide beside the peer-reviewed numbers from survodutide's MASH study. The survodutide column comes from a different population (adults with biopsy-confirmed MASH in a Phase 2 study), so don't read the two columns as a match.
| Side effect | Retatrutide, TRIUMPH-1, 80 weeks (company-announced, May 21, 2026): 4 mg / 9 mg / 12 mg vs placebo | Survodutide, MASH Phase 2, 48 weeks, 293 adults (peer-reviewed, NEJM 2024): survodutide vs placebo |
|---|---|---|
| Nausea | 28.6% / 38.4% / 42.4% vs 14.8% | 66% vs 23% |
| Diarrhea | 25.2% / 34.1% / 32.0% vs 13.5% | 49% vs 23% |
| Vomiting | 10.6% / 22.8% / 25.3% vs 4.8% | 41% vs 4% |
Dysesthesia. In TRIUMPH-1, abnormal skin sensation occurred in 5.1%, 12.3% and 12.5% on 4, 9 and 12 mg, vs 0.9% on placebo.
Heart rate and stomach effects in Phase 2. In the 2023 retatrutide Phase 2 study, heart rate rose with dose, peaking at 24 weeks, and stomach side effects were reduced by a lower starting dose. In the 46-week survodutide Phase 2 obesity study, 75% of people on survodutide had gastrointestinal events vs 42% on placebo (Lancet Diabetes and Endocrinology study, 2024).
Stopping treatment. In TRIUMPH-1, 4.1%, 6.9% and 11.3% (4, 9 and 12 mg) stopped because of any adverse event, vs 4.9% on placebo. In survodutide's Phase 3 trials, 19% stopped because of gastrointestinal-related side effects vs 2.9% on placebo in SYNCHRONIZE-1 (Boehringer's June 2026 release), and 18% vs 1.2% in SYNCHRONIZE-2. These are different measures, one counting any adverse event and the other counting only gastrointestinal events, so don't line them up side by side.
What do the liver studies show?
Survodutide has Phase 2 and Phase 3 liver results. In a 48-week Phase 2 study published in NEJM in 2024, 293 adults with liver disease (MASH) confirmed by biopsy received 2.4, 4.8 or 6.0 mg weekly or placebo. MASH improved without fibrosis getting worse in 47%, 62% and 43% of those groups, vs 14% on placebo. Liver fat fell by at least 30% in 63%, 67% and 57%, vs 14%. Fibrosis improved by at least one stage in 34%, 36% and 34%, vs 22% (NEJM 2024 MASH study).
In a Phase 3 liver-fat trial, SYNCHRONIZE-MASLD, 216 adults with obesity and fatty liver disease were treated for 48 weeks on 6.0 mg or placebo. Liver fat fell by at least 30% in 84.2% vs 24.3%, and weight fell 12.2% vs 1.0% on the efficacy count (Nature Medicine liver-fat study). This trial measured liver fat, not MASH resolution on biopsy.
Zealand's October 1, 2026 release says the FDA granted survodutide Breakthrough Therapy designation for MASH in September 2024, for non-cirrhotic MASH at stages F2 and F3 (Zealand's October 1, 2026 release). The LIVERAGE and LIVERAGE-Cirrhosis trials are still recruiting.
Retatrutide's liver-focused work is the SYNERGY-Outcomes master protocol, which includes retatrutide among its treatments for fatty liver disease (MASLD). It is recruiting, with an enrollment of 4,500 (ClinicalTrials.gov NCT07165028).
What do the heart outcome results show?
Each company has reported one cardiovascular outcomes result. Neither result shows a clear drop in heart events yet.
- Retatrutide, TRIUMPH-3 (adults with obesity and established cardiovascular disease, 80 weeks; Lilly, July 23, 2026, company-announced): the five-point measure, a combined count of major heart events, had a hazard ratio of 0.82 (95% interval 0.55 to 1.22), and the three-point measure had 1.12 (0.64 to 1.96). Neither was statistically significant, and Lilly said the trial saw fewer events than anticipated.
- Survodutide, SYNCHRONIZE-CVOT (5,530 adults with overweight or obesity plus cardiovascular disease, chronic kidney disease or at least two risk factors; 3.6 mg or 6.0 mg vs placebo; Zealand's November 9, 2026 announcement, company-announced): the five-point measure had a hazard ratio of 0.89 (95% interval 0.67 to 1.18), and the company says the non-inferiority goal was met. The three-point measure had 0.84 (0.60 to 1.18).
TRIUMPH-Outcomes, a retatrutide trial with about 10,000 participants, has a primary completion estimated for February 2029 (ClinicalTrials.gov NCT06383390).
Are either of these approved, and when could that happen?
Neither drug is approved, and no approval date exists for either. Lilly's July 23, 2026 release says it has the clinical data package to support global submissions and plans a U.S. submission in the first quarter of 2027 (Lilly's July 23, 2026 release). Zealand's November 9, 2026 announcement says Boehringer is moving forward with global regulatory submissions in obesity, and it gives no filing date.
Lilly says retatrutide is legally available only inside its clinical trials (Lilly's May 21, 2026 release).
For the full status check, see our guide, is retatrutide fda approved.
What the FDA says about unapproved versions sold online
The FDA's FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, says retatrutide cannot be used in compounding under federal law. It says FDA has warned firms selling unapproved semaglutide, tirzepatide, retatrutide, survodutide or mazdutide labeled “for research purposes” or “not for human consumption.” It also says the quality of these products is unknown, they may be harmful, and consumers should not buy them.
FDA's August 24, 2026 warning letter to a peptide seller says that, despite “research use only” labeling, its website showed the products were intended as drugs for human use.
Who do these results apply to, and who do they not?
The results describe the adults enrolled in each trial. TRIUMPH-1 and SYNCHRONIZE-1 enrolled adults with obesity and no diabetes. TRIUMPH-2 and SYNCHRONIZE-2 enrolled adults with type 2 diabetes. TRIUMPH-3 enrolled adults with obesity and established cardiovascular disease, and SYNCHRONIZE-CVOT enrolled adults with overweight or obesity plus cardiovascular disease, chronic kidney disease or at least two risk factors. TRIUMPH-4 enrolled adults with knee osteoarthritis, and SYNCHRONIZE-MASLD enrolled adults with fatty liver disease. People outside those groups aren't who these numbers describe. Your own clinician can talk through the approved options for your health history and other medicines.
Common mix-ups to avoid
- The mechanisms differ. Retatrutide acts on three receptors (GIP, GLP-1 and glucagon). Survodutide acts on two (GLP-1 and glucagon).
- The headline numbers aren't matched. Retatrutide's 28.3% and survodutide's 16.6% come from different trials, lengths and counting methods.
- Survodutide's 13.1% is the efficacy number. The NEJM paper's treatment-regimen figure for SYNCHRONIZE-2 is 9.8% at 6.0 mg.
- The makers differ. Retatrutide is Lilly's. Survodutide is Boehringer Ingelheim's, licensed from Zealand Pharma.
Questions to bring to your own clinician
Your own clinician can talk through the approved options. Neither of these two drugs can be prescribed, so these questions are about reading the results:
- Given my health history and my other medicines, what do these results mean for me?
- What do the stomach side effects and the skin-sensation signal mean for someone like me?
- What do the heart-trial results mean for my own heart risk?
- What does FDA's warning about unapproved versions sold online mean for my health decisions?
Your own clinician can talk through the approved options and weigh these numbers against your own health. Your next step this week: jot down your meals, water, movement and sleep, and watch your weight trend over a week, so you have a clear picture to share at that visit.
By the New Life Wellness Guide Editorial Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.